New on CCO Oncology!
Treatment Update
CME-Certified Interactive Virtual Presentations:
Advances in the Management of Bone Health in Multiple Myeloma
 |
James Berenson, MD, presents cases to illustrate key concepts of bone health in cancer patients, particularly those with multiple myeloma. Click here to begin.
|
Coming Soon!
 |
Management of Bone Health in Prostate Cancer Matthew R. Smith, MD, PhD |
 |
Management of Bone Health in Breast Cancer Robert E. Coleman, MD, FRCP |
Management Series
CME-Certified Modules:
  |
Clinical Considerations and Implications for Optimizing Outcomes in Patients With NHL Alice Mohr, RN, MSN, FNP-BC, and Deborah A. Frieze, PharmD, BCOP, review dosing regimens, critical safety issues, appropriate preventive care, and supportive care measures associated with the use of various therapeutic modalities for the treatment of non-Hodgkin’s lymphoma. |
CME-Certified Interactive Virtual Presentations:
 |
Evolving Options and Challenges in Mantle Cell Lymphoma Listen to a virtual presentation by Andre Goy, MD, as he provides a comprehensive overview of evolving treatment options for patients with mantle cell lymphoma, and test your knowledge of treatment options in the cases he presents. |
Coming Soon!
|

|
Current and Evolving Clinical Approaches: Indolent B-Cell Disorders Bruce D. Cheson, MD |
|

|
Clinical Approaches to Managing Patients with T-Cell Lymphoma Francine Foss, MD, PhD, FACP |
|

|
Clinical Considerations and Strategies for Managing Patients With DLBCL Richard I. Fisher, MD |
CCO Downloadable Slideset:
Treatment Update
CME-Certified Modules:
State-of-the-Art First-line Treatment of MCL: Current and Novel Approaches
 |
Andrew D. Zelenetz, MD, PhD, reviews the latest data on current and novel therapeutic approaches for frontline treatment of mantle cell lymphoma. |
New Options for the Treatment of Relapsed Mantle Cell Lymphoma
 |
Steven H. Bernstein, MD, explores current recommendations and options for the treatment of advanced mantle cell lymphoma and discusses what recent clinical trial results may signify for patients. |
The Role of Maintenance Therapy and Individualization of Therapy in Mantle Cell Lymphoma
 |
Sven de Vos, MD, PhD, reviews the current status of maintenance therapy for mantle cell lymphoma and explores new developments in prognostic measures and markers that may lead to the individualization of therapy. |
Practical Nursing Management Considerations in Mantle Cell Lymphoma
| Amy Goodrich, RN, MSN, CRNP-AC, reviews current strategies to optimally manage therapy-related adverse effects in patients with mantle cell lymphoma. |
CCO Downloadable Slideset:
Practical Nursing Management Considerations in Mantle Cell Lymphoma
 |
Download slides on important nursing considerations for patients who are receiving medical therapy for mantle cell lymphoma. |
Treatment Update
Treatment Update
Expert review and Interactive Virtual Presentations on treatment options in acute lymphoblastic leukemia.
CME-Certified Module:
Current Treatment Options in Acute Lymphoblastic Leukemia
 |
Dan Douer, MD, reviews current standards of care for adults and children with ALL and explores changes in the treatment landscape with the potential to improve outcomes. |
CME-Certified Interactive Virtual Presentations:
Allogeneic Transplantation for Ph+ Acute Lymphoblastic Leukemia
 |
Jacob M. Rowe, MD, FACP, explores current thinking regarding treatment strategies for adults with acute lymphoblastic leukemia. |
ALL in Special Populations: Adolescents/Young Adults and Older Adults
 |
Adele K. Fielding, MB BS, PhD, FRCP, FRCPath, reviews strategies to improve treatment outcomes in 2 special patient populations affected by ALL: young adults and the elderly. |
Downloadable PowerPoint Slidesets:
CCO Conference Coverage
CCO's independent coverage of the 2009 Clinical Oncology meeting includes Capsule Summaries of key presentations, as well as Expert Analyses, Slides, Expert Recaps, and audio Expert Highlights that focus on key issues highlighted at the conference.
- Breast Cancer
Robert S. Mocharnuk, MD, William J. Gradishar, MD, FACP, Kathy D. Miller, MD, Mark D. Pegram, MD
- Colorectal Cancer
Anthony El-Khoueiry, MD, Edward Chu, MD, Richard M. Goldberg, MD, Alan P. Venook, MD, Anthony El-Khoueiry, MD
- Hematologic Malignancies
Edward A. Stadtmauer, MD, Kenneth Anderson, MD, Andre Goy, MD, Susan M. O’Brien, MD
- Lung Cancer
Barbara J. Gitlitz, MD, David R. Gandara, MD, Ramaswamy Govindan, MD, Corey J. Langer, MD, FACP
Treatment Update
Suzanne George, MD, reviews current and evolving treatment of sarcoma.
Treatment Update
Expert faculty members review and explore regional and systemic treatment strategies for the clinical management of patients with hepatocellular carcinoma.
Now Available!
Video Panels:
Treatment Update
CME-Certified Module:
CME-Certified Virtual Presentation:
Downloadable PowerPoint Slideset:
Coming Soon!
Interactive Decision Making Tool
Treatment Update
Through 3 Virtual Presentations and associated downloadable slidesets and an audio archive, CCO’s expert faculty members explore current thinking regarding the treatment of glioblastoma.
CME-Certified Virtual Presentations: Glioblastoma: Understanding the Challenge
 |
David Schiff, MD, provides a clinical overview of glioblastoma and reviews the genetic pathways involved in its pathogenesis, along with a discussion of MGMT methylation as a prognostic biomarker and tools for predicting survival in patients with glioblastoma. |
Current Treatment Options and Recommendations for Patients With GBM
 |
Tracy Batchelor, MD, MPH, reviews current treatment options and evidence-based recommendations for recurrent GBM. |
Clinical Explorations With Targeted Agents in Recurrent GBM
 |
Timothy Cloughesy, MD, reviews targeted agents under investigation for the treatment of glioblastoma and discusses the issue of resistance when using these drugs in this setting. |
Downloadable Powerpoint Slidesets:
Glioblastoma: Understanding the Challenge
 |
David Schiff, MD, reviews the epidemiology, genetic factors, and prognostic biomarkers of glioblastoma. | Current Treatment Options and Recommendations for Patients with GBM
 |
Tracy Batchelor, MD, MPH, discusses current treatment standards for patients with glioblastoma. | Clinical Explorations With Targeted Agents in Recurrent GBM
 |
Timothy Cloughesy, MD, discusses investigational targeted agents for recurrent glioblastoma. |
Downloadable Audio Archive:
Expert Insights: Issues in the Management of Glioblastoma Patrick Y. Wen, MD discusses important issues in the management of patients with glioblastoma, including current treatment options, the role of biomarkers in selecting optimal treatment, and the future of targeted therapies.
CCO Conference Coverage
CCO’s expert faculty members explore results presented at the 2008 Thoracic Oncology meeting through 3 Conference Reports and a downloadable slideset.
CME-Certified Conference Reports:
- Multimodality Therapy in Non-Small-Cell Lung Cancer
Jeffrey D. Bradley, MD. and Benjamin Movsas, MD, review and discuss recent data on combined therapeutic approaches for non-small-cell lung cancer.
- Integration of Targeted Therapy and Traditional Chemotherapy in Advanced Non-Small-Cell Lung Cancer
Join Ramaswamy Govindan, MD, and Giorgio V. Scagliotti, MD, PhD, as they review the most relevant new data on the use of targeted therapies for the treatment of non-small-cell lung cancer.
- Advances in Small-Cell Lung Cancer and the Role of Marker Analysis in Advanced Non-Small-Cell Lung Cancer
Expert faculty members respond to frequently asked questions about HIV tropism, tropism testing, and the implications for clinical management of patients.
Downloadable PowerPoint Slideset: CCO Independent Conference Coverage of the 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology
 |
Downloadable slideset highlighting some of the most significant data presented on multimodality therapy, targeted therapy, and the utility of molecular markers in lung cancer. |
CCO Conference Coverage
Through 4 downloadable slidesets, CCO’s expert faculty members focus on the role of molecular therapies in the treatment of ovarian cancer.
- The Need for Molecular-Targeted Therapy
Michael V. Seiden, MD, PhD, reviews the role of molecular-targeted therapy in ovarian cancer.
- VEGF Targeted Therapy in Ovarian Cancer: Basis & Directions
Robert A. Burger, MD, discusses the rationale for using VEGF inhibitors in ovarian cancer and reviews current phase II and III trials evaluating these agents in the frontline and recurrent setting.
- Targeting EGF and Other Signal Transduction Pathway
Thomas J. Herzog, MD, discusses targeting EGF and other approaches such as Src inhibition, c-Met inhibition, PARP inhibition, and mTOR inhibition as therapy for ovarian cancer.
- Immunologic-Targeted Therapy in Ovarian Cancer
George Coukos, MD, PhD, discusses immunologic-targeted therapy as a therapeutic strategy for ovarian cancer.
Treatment Update
This Treatment Update helps clinicians apply current thinking regarding maintaining and optimizing bone health in cancer patients through 4 CME-certified educational modules.
More Treatment Updates
More CCO Independent Conference Coverage
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
More Interactive Case Challenges
Liver Metastases in CRC
Multiple Myeloma
|
Browse Oncology
Resource Center
This resource has been specific designed to meet the educational needs of oncology nurses. Check regularly for the latest conference coverage, treatment updates and plenty of free CE hours. Click here.
CCO Video Highlights
FEATURED VIDEO SEGMENT Expert Highlight: ESAs in Cancer
David P. Steensma, MD, describes a patient-level meta-analysis on the effect of ESAs on the survival of cancer patients and the implications for patient care. Click here.
New Data
Following 24 months of adjuvant aromatase inhibitor therapy in women with breast cancer and androgen deprivation therapy in men with prostate cancer, denosumab increased BMD at selected skeletal sites; safety profile of denosumab was similar to that of placebo.
Click here for related capsule summaries
Slidesets
Bookstore
Cases
Expert Commentary
from our Advisory Board & leading experts
Expert Viewpoint for March 2009
Howard Liebman, MD
Chief, Hematology Section Professor of Medicine and Pathology Keck School of Medicine of the University of Southern California Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases Norris Cancer Hospital Los Angeles, California
Resource Centers
Access CCO's most compelling content on oncology nursing from a single convenient page
|